Kyowa Kirin Announces Acceptance for Presentations at the Eu

Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients

Related Keywords

Berlin , Germany , Japan , Tokyo , United States , America , Ehsanollah Esfandiari , Hirotaka Mano , Kenji Kabashima , Emma Guttman Yassky , Asia Pacific , Camilla Chong , European Academy Of Dermatology , Jolla Institute For Immunology , A Global Specialty Pharmaceutical Company , Kyowa Kirin Us Research , Prnewswire Kyowa Kirin Co Ltd , Amgen , European Academy , Poster Title , Phd Date , Kyowa Kirin , Kyowa Kirin Collaborationon June , Kyowa Kirinkyowa Kirin , North America , Kyowa , Study , Data ,